Latest News

The safety and efficacy of the Break Wave device was assessed in the pivotal SOUND trial.

The ARID platform is evaluating the safety and efficacy of the Voro Urologic Scaffold in minimizing stress urinary incontinence following robot-assisted radical prostatectomy.

The phase 3 BiPASS trial is assessing earlier use of 68Ga-PSMA-PET imaging in the pre-biopsy setting.

Enrollment in the ongoing pivotal QUILT-2.005 trial has now reached 85%.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Stephen J. Freedland, MD, about the role of diet and nutrition in prostate cancer risk and outcomes.

The Safety Review Committee has recommended that the trial proceed with the cohort expansion phase with no modifications to the protocol.

The next step is to prospectively validate the model in real-world clinical settings or within ongoing clinical trials.

Image-guided radiotherapy with reduced target margins may improve some dosimetric parameters and patient-reported urinary symptoms.

The phase 2 study is looking to evaluate nadofaragene firadenovec in combination with the investigational light-activated small molecule TLD-1433 (Ruvidar).

Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group.

The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.

Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.